Please login to the form below

Not currently logged in
Email:
Password:

anxiety

This page shows the latest anxiety news and features for those working in and with pharma, biotech and healthcare.

Pear Therapeutics submits latest digital therapeutic, insomnia and depression treatment

Pear Therapeutics submits latest digital therapeutic, insomnia and depression treatment

Pear Therapeutics says the study also showed improvements in anxiety symptoms (as measured by the General Anxiety Disorder 7-item (GAD-7) scale), with a treatment arm mean of 3.16

Latest news

More from news
Approximately 1 fully matching, plus 145 partially matching documents found.

Latest Intelligence

  • Changing healthcare communications Changing healthcare communications

    Replacing anxiety with confidence, mediocrity with purpose. By David Hunt and Lou Shipley. ... But only if we replace anxiety with confidence, mediocrity with purpose, and attract the brightest, smartest and most creative minds to join our cause.

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    There were also significant improvements for AbbVie’s drug over Humira on quality of life measures and over Stelara on anxiety and depression, and risankizumab did better than both comparator drugs

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    Galbraith is concerned about the rise in reported anxiety and mental health problems in young people, with young women most vulnerable.

  • The Patient Safety Challenge The Patient Safety Challenge

    There were anxieties about how reporting could affect their reputations and career prospects.

  • Finding the patient voice Finding the patient voice

    This data provided the big picture about what motivates people to join clinical trials, their anxieties and their experiences. ... we should communicate with them, depending on their needs and anxieties.

More from intelligence
Approximately 0 fully matching, plus 17 partially matching documents found.

Latest appointments

  • Dr Niall Murphy and Pierre Schwich join Pharnext Dr Niall Murphy and Pierre Schwich join Pharnext

    Prior to this, Dr Murphy served as a unit leader for a team of scientists collaborating on research in the areas of addition biology, Alzheimer's disease, anxiety, depression and neurotoxicity

  • Turing names Eliseo Salinas as head of R&D Turing names Eliseo Salinas as head of R&D

    Salinas has played a leading role in numerous programmes for a range of diseases and disorders, with specific focus on central nervous systems (CNS) condition such as depression and anxiety, schizophrenia,

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 25 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics